Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II
Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Patients receive abiraterone acetate orally daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients receive androgen blockade with GNRH agonist (goserelin acetate or leuprolide acetate) or a GNRH antagonist (degarelix) per the treating physician and this will be given continuously until evidence of disease progression. Bilateral surgical orchiectomy is also acceptable.
After completion of study therapy, patients are followed up every 3 months for 1 year and then every 6 months for up to 3 years.
DISEASE CHARACTERISTICS:
Histologically or cytologically proven diagnosis of adenocarcinoma of the prostate
Metastatic (M1) disease as evidenced by soft tissue and/or bony metastases at the time of initiation of androgen-deprivation therapy (ADT)
Must have at least one of the following:
No small cell or neuroendocrine prostate cancer
Patients must be receiving ADT (e.g., gonadotropin-releasing hormone [GNRH] antagonist, with or without antiandrogen) prior to entering this study
Suboptimal response to ADT induction as defined by the following criteria:
Declining PSA (current PSA is less than the PSA prior to starting ADT) that fails to reach 4 ng/mL or below despite continuous ADT
PSA of > 4 ng/mL must be observed between 6-12 months after the initiation of ADT
Documentation of failure to achieve this PSA of ≤ 4 ng/mL must be within 28 days of registration
If the PSA is declining or stable (defined as a PSA rise ≤ 0.1 ng/mL from nadir) and the patient is on an antiandrogen, they must remain on the antiandrogen
Patients with stable or declining PSA who have had previous antiandrogen exposure, but are not taking an antiandrogen at the time of registration, must wait at least 6 weeks from the last antiandrogen dose before registration and still demonstrate a stable or falling PSA which is > 4 ng/mL by month 12, in order to be eligible
If the PSA is rising and they are on an antiandrogen, formal antiandrogen washout must be performed (4 weeks for flutamide and 6 weeks for bicalutamide and nilutamide with no evidence of a falling PSA after washout)
No patients with radiographic progression when compared to available imaging studies performed prior to starting the GNRH agonist/antagonist therapy
Patients who have measurable disease must have radiographic assessment (at least an abdominal/pelvic CT scan) within 28 days prior to registration
Non-measurable disease must be assessed (i.e., bone scan) within 42 days prior to registration
No patients with a history of brain metastases or who currently have treated or untreated brain metastases
PATIENT CHARACTERISTICS:
Zubrod performance status 0-2
ANC ≥ 1,500/μL
Platelet count ≥ 100,000/μL
Hemoglobin ≥ 10 g/dL
Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) OR creatinine clearance ≥ 60 mL/min
Bilirubin ≤ 1.5 times ULN (unless documented Gilbert disease)
AST and ALT < 1.5 times ULN
Potassium ≥ 3.5 mmol/L
Patient must have a testosterone value of < 50 ng/dL obtained within 28 days prior to registration
Patients must have controlled blood pressure defined as systolic blood pressure < 160 mm Hg and diastolic blood pressure < 95 mm Hg
Patients who have partners of child-bearing potential must be willing to use a method of birth control with adequate barrier protection during the study and for 1 week after the last study drug administration
Must be able to take oral medication without crushing, dissolving, or chewing tablets
Patients must not have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of abiraterone acetate
No other prior malignancy is allowed except for any of the following:
No patients with active or symptomatic viral hepatitis or chronic liver disease
No history of NYHA class III or IV heart failure
No known allergies, hypersensitivity, or intolerance to abiraterone acetate, prednisone, or their excipients
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
Patients with a history of prior neoadjuvant or adjuvant GNRH agonist/antagonist therapy (related to previous surgery or radiation) are eligible provided they finished this therapy at least two years prior to registration
At least 6 weeks since prior and no concurrent finasteride or dutasteride
At least 28 days since prior radiotherapy or surgery and recovered
At least 4 weeks since prior investigational products
At least 4 weeks since prior flutamide (6 weeks for bicalutamide and nilutamide) with no evidence of a falling PSA
No prior or concurrent cytotoxic chemotherapy or radiopharmaceuticals for prostate cancer
No prior or concurrent ketoconazole for the treatment of prostate cancer
Not requiring more than 10 mg a day of prednisone for another medical indication
Not planning to receive any concurrent cytotoxic chemotherapy, immunotherapy, surgery, or radiotherapy during protocol treatment
No concurrent hormonal-acting agents, including diethylstilbestrol/DES, aldosterone, PC-SPES, or spironolactone
No concurrent antifungal medication (e.g., fluconazole or itraconazole)
No medications that alter cardiac conduction
No prior Provenge (sipuleucel-T)
Little Rock, Arkansas 72205, United States
Marysville, California 95901, United States
San Francisco, California 94115, United States
Santa Clara, California 95051, United States
South San Francisco, California 94080, United States
Aurora, Colorado 80045, United States
Grand Junction, Colorado 81502, United States
Hartford, Connecticut 06105, United States
Boise, Idaho 83706, United States
Boise, Idaho 83712, United States
Maywood, Illinois 60153, United States
Normal, Illinois 61761, United States
Kansas City, Kansas 66160-7357, United States
Wichita, Kansas 67214, United States
Lafayette, Louisiana 70503, United States
Shreveport, Louisiana 71130-3932, United States
Dearborn, Michigan 48123-2500, United States
Grosse Pointe Woods, Michigan 48236, United States
Billings, Montana 59102, United States
Missoula, Montana 59807, United States
Middletown, New York 10940-4199, United States
Rochester, New York 14642, United States
Charlotte, North Carolina 28233-3549, United States
Charleston, South Carolina 29425, United States
Kingsport, Tennessee 37662, United States
Houston, Texas 77030, United States